Early Feasibility Study of the MyoRegulator® for Treatment of ALS

Amyotrophic Lateral Sclerosis Clinical Trial

— ALSEFS  

Official title:

Early Feasibility Study of the MyoRegulator® for Treatment of ALS

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06165172
• Other study ID #: PMN-004
• Status: Recruiting
• Phase: N/A
• Start date: June 21, 2023
• Est. completion date: July 31, 2024

Study information

• Verified date: December 2023
• Source: PathMaker Neurosystems Inc.
• Contact: Sheila Hemeon-Heyer, MSc, JD
• Phone: 413-330-8578
• Email: sheila.heyer[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-center, single-arm, open-label study aiming to assess the safety and feasibility of the MyoRegulator® device when used to treat individuals with amyotrophic lateral sclerosis (ALS). This study is the first use of the MyoRegulator® device to treat individuals with ALS. The main objective of this study is to confirm that individuals with ALS can tolerate the study treatment regimen without any evidence of serious adverse events related to the use of the device.

The MyoRegulator® device is a non-significant risk (NSR) investigational non-invasive neuromodulation device that uses multi-site direct current (multi-site DCS) stimulation. It has been used in two completed clinical trials evaluating its efficacy to treat post-stroke muscle spasticity and is currently being evaluated in a third trial in this post-stroke population.

Description:

Amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease) is a progressive neurodegenerative disease that affects motor neurons in spinal cord and brain. ALS causes motor and cognitive function deficits and eventual death, typically within 2-5 years of diagnosis. There are at least 30,000 ALS patients in the United States and about 5,000 new diagnoses every year according to the Centers for Disease Control (CDC).

Recent research has established important links between ALS and motor neuron hyperexcitability and suggest that motor neuron hyperexcitability is found across different ALS variants.

The multi-site DCS MyoRegulator® treatment is a non-invasive approach to the suppression of motor neuron hyperexcitability based on multi-site direct current stimulation (DCS). Pre-clinical studies show that treatment using multi-site DCS effectively slows disease progression in transgenic mouse models of ALS. This is associated with improved motor function, preservation of motor neurons, and improved animal survival.

This clinical study is a non-significant risk (NSR) investigation using the non-invasive multi-site DCS MyoRegulator® to evaluate the feasibility and safety of treatment with MyoRegulator® in individuals with ALS. The primary endpoint is feasibility and safety. Feasibility will be evaluated by recording and assessing the proportion potential participants who are enrolled from the total number of participants screened for the study, the ease of delivering treatment, the tolerability of study participants to the treatment, and the compliance of study participants with the study schedule and evaluations. Safety will be evaluated by recording the frequency and duration of any adverse events reported by study participants or observed by physical examination during or following treatment and throughout the study duration.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 5
• Est. completion date: July 31, 2024
• Est. primary completion date: May 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years of age or older

• A clinical diagnosis of ALS as confirmed by medical history

• Willing to forgo botulinum toxin, phenol or alcohol injections, intrathecal baclofen, digitalis, and morphine for the study duration

• Willing to refrain from participation in any other clinical trial for the duration of this study

• Willing to forgo pregnancy for the duration of the study

• Willing and able to give informed consent or have informed consent provided for them by their legal guardian

• Cognitive function sufficient to understand the study and follow instructions (per interview with appropriate clinician)

Exclusion Criteria:

• Study participants who are on permanent assisted ventilation (PAV) defined as >22h of noninvasive or invasive ventilation a day for > 7 consecutive days.

• Implanted intrathecal pump

• Prior botulinum toxin injection(s) within 12 weeks of study enrollment

• Prior phenol or alcohol injections within 6 months of study enrollment

• Presence of potential risk factors for trans-spinal direct current stimulation:

• Damaged skin at the stimulation sites (i.e., skin with ingrown hairs, acne, razor nicks, wounds that have not healed, recent scar tissue, broken skin, etc.)

• Lack of sensory perception at the stimulation sites

• Presence of an electrically, magnetically, or mechanically activated implant (including cardiac pacemaker) or any other electrically sensitive support system with the exception of loop recorders

• Ferrous metal in the path of the current flow (jewelry must be removed during stimulation)

• Past history of epileptic seizures or unexplained spells of loss of consciousness during the previous 36 months

• Any medical condition that would prevent the participant from being able to participate in the clinical outcome measures

• Pregnant females, as determined by a pregnancy test at enrollment (in females of child-bearing potential)

Related Conditions & MeSH terms

• Amyotrophic Lateral Sclerosis
• Motor Neuron Disease
• Sclerosis

Intervention

Device:
• MyoRegulator®
Study participants will receive treatment using the MyoRegulator® device 3 times a week for 2 x 30 minutes per session. The first week of treatment will be followed by a 1-week rest period with no treatments. Treatment sessions will then resume for 4 consecutive weeks, 3 times per week. A follow-up visit will be scheduled 4 weeks after the last treatment session.

Locations

Country	Name	City	State
United States	Spaulding Rehabilitation Hospital	Charlestown	Massachusetts

Sponsors (4)

Lead Sponsor	Collaborator
PathMaker Neurosystems Inc.	Muscular Dystrophy Association, Sean M. Healey & AMG Center for ALS, Spaulding Rehabilitation Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety as measured by number of patients with any device-related serious adverse event	Safety will be evaluated by recording the frequency, severity, and duration of any adverse events reported by study participants or observed by physical examination during or following treatment and throughout the study duration.	Up to 4 weeks following the last treatment
Primary	Tolerability as measured by patient's ability to complete the treatments	Treatment tolerability will be evaluated by assessing the ease of delivering treatment, the tolerability of study participants to the treatment, and the compliance of study participants with the study schedule and evaluations.	Up to 4 weeks following the last treatment
Secondary	Improvement in Functionality	Change in Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) score following treatment as compared to baseline. The ALSFRS-R measures 12 aspects of physical function, ranging from one's ability to swallow and use utensils to climbing stairs and breathing. Each function is scored from 0 (no ability) to 4 (normal), with a summed total score from 0 (worst) to 48 (best).	Up to 4 weeks following the last treatment
Secondary	Improvement in Activities of Daily Living	Change in Rasch Overall ALS Disability Scale (ROADS) score following treatment as compared to baseline.; The ROADS is a patient-reported outcome measure that assesses overall disability level in people with ALS. The scale contains 28 items, each scored 0 (unable to perform), 1 (can perform but with difficulty), or 2 (normal performance) and a summed total score from 0 (worst) to 56 (best).	Up to 4 weeks following the last treatment
Secondary	Improvement in Quality of Life	Change in Amyotrophic Lateral Sclerosis Assessment Questionnaire - 40 (ALSAQ-40) score following treatment as compared to baseline. The ALSAQ-40 consists of 40 questions about how well the patient can perform tasks in 5 areas: physical mobility, activities of daily living and independence, eating and drinking, communication, and emotional reactions. Each task is rated on a five-point scale from 0 = can't do, to 4 = normal ability with a summed total score from 0 (worst) to 40 (best).	Up to 4 weeks following the last treatment